Replies to post #94555 on Biotech Values

[genisi]

Erbitux wasn't one of the 4 drugs tested in the BATTLE program but at least one study concludes "In contrast with colorectal cancer, and within the limitations of the data set, efficacy parameters did not appear to correlate with K-Ras mutation status or with any of the EGFR-related biomarkers evaluated. Additional exploratory analyses are essential to identify predictive markers and to optimize patient selection for cetuximab therapy in NSCLC."

http://jco.ascopubs.org/cgi/content/abstract/28/6/918

Edit
Found another:

"Conclusions: These data suggest that KRAS mutations may not play a significant predictive role for cetuximab-based therapy in NSCLC, contrary to colorectal cancer."

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33350

[DFRAI]

Erbitux fits nicely with the reovirus from ONCY
we are talking 70-100% tumor regression.

[biomaven0]

I concur with genisi that Erbitux hasn't been shown to helpful in K-RAS mutations in NSCLC (nor has anything else to my knowledge).

This article seems to be a good summary of state of play:

http://www.cancernetwork.com/cme/article/10165/1430608